8.30
-0.19(-2.24%)
Currency In NaN
| Previous Close | 8.49 |
| Open | 8.46 |
| Day High | 8.48 |
| Day Low | 8.2 |
| 52-Week High | 19.58 |
| 52-Week Low | 4.88 |
| Volume | 49,251 |
| Average Volume | 62,447 |
| Market Cap | 180.08M |
| PE | -4.91 |
| EPS | -1.69 |
| Moving Average 50 Days | 12.05 |
| Moving Average 200 Days | 10.98 |
| Change | -0.19 |
Aardvark Therapeutics to Present at Upcoming Investor Conferences in September
GlobeNewswire Inc.
Aug 27, 2025 8:10 PM GMT
SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the
Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy
GlobeNewswire Inc.
Aug 12, 2025 12:00 PM GMT
In a gold-standard model of obesity, treatment with ARD-201 resulted in approximately 19% body weight reduction after 30 days of treatment.ARD-201 was also associated with attenuated weight regain after discontinuation of tirzepatide.In combination w
Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
GlobeNewswire Inc.
Jul 18, 2025 12:00 PM GMT
SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics for the treatment of metabolic diseases, today a